Study to determine the durability of glycaemic control with early treatment with a vildagliptin-metformin combination regimen vs. standard-of-care metformin monotherapy—the VERIFY trial: a randomized double-blind trialDEL PRATO, S; FOLEY, J. E; KOTHNY, W et al.Diabetic medicine. 2014, Vol 31, Num 10, pp 1178-1184, issn 0742-3071, 7 p.Article

DPP4-inhibitor improves neuronal insulin receptor function, brain mitochondrial function and cognitive function in rats with insulin resistance induced by high-fat diet consumptionPIPATPIBOON, Noppamas; PINTANA, Hiranya; PRATCHAYASAKUL, Wasana et al.European journal of neuroscience (Print). 2013, Vol 37, Num 5-6, pp 839-849, issn 0953-816X, 11 p.Article

Treatment adherence with vildagliptin compared to sulphonylurea as add-on to metformin in Muslim patients with type 2 diabetes mellitus fasting during RamadanHANIF, W; MALIK, W; HASSANEIN, M et al.Current medical research and opinion. 2013, Vol 29, Num 7, pp 807-811, issn 0300-7995, 5 p.Article

A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized studyFILOZOF, C; GAUTIER, J.-F.Diabetic medicine. 2010, Vol 27, Num 3, pp 318-326, issn 0742-3071, 9 p.Article

In vivo profiling of DPP4 inhibitors reveals alterations in collagen metabolism and accumulation of an amyloid peptide in rat plasmaJOST, Marco M; LAMERZ, Jens; JÜRGENS, Michael et al.Biochemical pharmacology. 2009, Vol 77, Num 2, pp 228-237, issn 0006-2952, 10 p.Article

The Dipeptidyl Peptidase-4 Inhibitor Vildagliptin Improves β-Cell Function and Insulin Sensitivity in Subjects With Impaired Fasting GlucoseUTZSCHNEIDER, Kristina M; TONG, Jenny; DEACON, Carolyn F et al.Diabetes care. 2008, Vol 31, Num 1, pp 108-113, issn 0149-5992, 6 p.Article

New Drugs for Type 2 Diabetes Mellitus : What is their Place in Therapy?KRENTZ, Andrew J; PATEL, Mayank B; BAILEY, Clifford J et al.Drugs (Basel). 2008, Vol 68, Num 15, pp 2131-2162, issn 0012-6667, 32 p.Article

Vildagliptin : A Review of its Use in the Management of Type 2 Diabetes MellitusCROXTALL, Jamie D; KEAM, Susan J.Drugs (Basel). 2008, Vol 68, Num 16, pp 2387-2409, issn 0012-6667, 23 p.Article

Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metforminBOSI, Emanuele; CAMISASCA, Riccardo Paolo; COLLOBER, Carole et al.Diabetes care. 2007, Vol 30, Num 4, pp 890-895, issn 0149-5992, 6 p.Article

The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patientsBALAS, Bogdan; BAIG, Muhammad R; CUSI, Kenneth et al.The Journal of clinical endocrinology and metabolism. 2007, Vol 92, Num 4, pp 1249-1255, issn 0021-972X, 7 p.Article

The role of vildagliptin in the management of type 2 diabetes mellitusKLAPPINGER, Erika L; HALMA, K.The Annals of pharmacotherapy. 2007, Vol 41, Num 5, pp 824-832, issn 1060-0280, 9 p.Article

VildagliptinHENNESS, Sheridan; KEAM, Susan J; EVANS, Marc et al.Drugs (Basel). 2006, Vol 66, Num 15, pp 1989-2004, issn 0012-6667, 16 p.Article

Inhibition of dipeptidyl-peptidase IV catalyzed peptide truncation by Vildagliptin ((2S)-{[(3-hydroxyadamantan-1-yl)amino]acetyl}-pyrrolidine-2-carbonitrile)BRANDT, Inger; JOOSSENS, Jurgen; XIN CHEN et al.Biochemical pharmacology. 2005, Vol 70, Num 1, pp 134-143, issn 0006-2952, 10 p.Article

Vildagliptin, a DPP-4 inhibitor for the twice-daily treatment of type 2 diabetes mellitus with or without metforminFORST, Thomas; BRAMLAGE, Peter.Expert opinion on pharmacotherapy. 2014, Vol 15, Num 9, pp 1299-1313, issn 1465-6566, 15 p.Article

Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes: Meta-AnalysisPARK, Haesuk; PARK, Chanhyun; KIM, Yoona et al.The Annals of pharmacotherapy. 2012, Vol 46, Num 11, pp 1453-1469, issn 1060-0280, 17 p.Article

Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Type 2 Diabetes MellitusNEUMILLER, Joshua J; WOOD, Lindy; CAMPBELL, R. Keith et al.Pharmacotherapy. 2010, Vol 30, Num 5, pp 463-484, issn 0277-0008, 22 p.Article

Spécificités et complexité de la prise en charge du diabète de type 2 chez le sujet âgé: importance des hypoglycémies et apport potentiel de la vildagliptine, une nouvelle option thérapeutique = Management of type 2 diabetes in the elderly: assessing the role of vildagliptin, a novel therapeutic optionDEJAGER, Sylvie; VIRALLY, Marie-Laure; PENFORNIS, Alfred et al.La Revue de gériatrie. 2010, Vol 35, Num 5, pp 333-340, issn 0397-7927, 8 p.Article

Disposition of Vildagliptin, a Novel Dipeptidyl Peptidase 4 Inhibitor, in Rats and DogsHANDAN HE; TRAN, Phi; HEQUN YIN et al.Drug metabolism and disposition. 2009, Vol 37, Num 3, pp 545-554, issn 0090-9556, 10 p.Article

LES INCRÉTINES [ANALOGUES DU GLP-1 ET INHIBITEURS DE LA DPP-4] DANS LE TRAITEMENT DU DIABÈTE DE TYPE 2PREUMONT, V.Louvain médical. 2009, Vol 128, Num 3, issn 0024-6956, S37-S45Conference Paper

Characterization of the Influence of Vildagliptin on Model-Assessed β-Cell Function in Patients with Type 2 Diabetes and Mild HyperglycemiaMARI, Andrea; SCHERBAUM, Werner A; NILSSON, Peter M et al.The Journal of clinical endocrinology and metabolism. 2008, Vol 93, Num 1, pp 103-109, issn 0021-972X, 7 p.Article

Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes : a 24-week, double-blind, randomized trialPAN, C; YANG, W; BARONAT, J. P et al.Diabetic medicine. 2008, Vol 25, Num 4, pp 435-441, issn 0742-3071, 7 p.Article

Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitusLANGLEY, Alissa K; SUFFOLETTA, Terri J; JENNINGS, Heath R et al.Pharmacotherapy. 2007, Vol 27, Num 8, pp 1163-1180, issn 0277-0008, 18 p.Article

Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitusHE, Yan-Ling; SERRA, Denise; YIBIN WANG et al.Clinical pharmacokinetics. 2007, Vol 46, Num 7, pp 577-588, issn 0312-5963, 12 p.Article

The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteersHE, Yan-Ling; SADLER, Brian M; SABO, Ron et al.Clinical pharmacokinetics. 2007, Vol 46, Num 9, pp 787-802, issn 0312-5963, 16 p.Article

The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretionEL-OUAGHLIDI, Andrea; REHRING, Erika; HOIST, Jens J et al.The Journal of clinical endocrinology and metabolism. 2007, Vol 92, Num 11, pp 4165-4171, issn 0021-972X, 7 p.Article